TABLE 3.
Factors associated with chemotherapy‐triggered exacerbation of ILD following univariate and multivariate analyses
| Univariate analysis | Multivariate analysis | |||||
|---|---|---|---|---|---|---|
| Factors | OR | 95% CI | p‐value | OR | 95% CI | p‐value |
| Age, per year increment | 0.93 | 0.86–1.01 | 0.105 | 0.89 | 0.80–0.98 | 0.026 |
| Sex (Female vs. Male) | 0.64 | 0.18–2.17 | 0.474 | 0.71 | 0.11–4.31 | 0.712 |
| Performance status (0, 1 vs. 2–4) | 1.38 | 0.24–7.88 | 0.712 | |||
| BMI, per kg/m2 increment | 0.92 | 0.77–1.11 | 0.417 | 0.98 | 0.79–1.22 | 0.921 |
| Histology (adenocarcinoma vs. nonadenocarcinoma) | 0.60 | 0.19–1.86 | 0.382 | |||
| Clinical stage (III vs. IV or recurrence) | 1.37 | 0.34–5.54 | 0.651 | |||
| LD, per U/l increment | 1.00 | 0.99–1.01 | 0.072 | |||
| KL‐6, per U/ml increment | 1.00 | 1.00–1.00 | 0.353 | |||
| % predicted FVC, per % increment | 0.96 | 0.94–0.99 | 0.035 | 0.96 | 0.93–0.99 | 0.026 |
| % predicted DLCO, per % increment (n = 28) | 0.73 | 0.95–1.03 | 0.993 | |||
| Sarcopenia (No vs. Yes) | 3.87 | 1.12–13.33 | 0.032 | 6.39 | 1.09–37.26 | 0.039 |
Abbreviations: BMI, body mass index; CI, confidence interval; DLCO, diffuse capacity of the lung for carbon monoxide; FVC, forced vital capacity; KL‐6, Krebs von den Lungen 6; LD, lactate dehydrogenase; ILD, interstitial lung disease; OR, odds ratio.